Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Arvinas	I-Mab	Hypera	Agios Pharmaceuticals	FibroGen
Symbol	NASDAQ:ARVN	NASDAQ:IMAB	OTCMKTS:HYPMY	NASDAQ:AGIO	NASDAQ:FGEN
Price Information
Current Price	$64.69	$57.00	$6.27	$54.69	$19.91
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.5	1.2	0.9	1.3	1.8
Analysis Score	3.5	2.5	0.0	2.4	4.1
Community Score	2.3	3.3	2.6	2.7	2.5
Dividend Score	0.0	0.0	0.8	0.0	0.0
Ownership Score	1.7	0.0	0.0	1.7	1.7
Earnings & Valuation Score	0.0	0.0	1.3	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$106.45	$70.00	N/A	$64.64	$45.83
% Upside from Price Target	64.56% upside	22.81% upside	N/A	18.19% upside	130.20% upside
Trade Information
Market Cap	$3.16 billion	$4.10 billion	$3.97 billion	$3.82 billion	$1.82 billion
Beta	2.14	N/A	0.96	1.8	1.59
Average Volume	487,086	358,169	15,865	782,301	1,475,040
Sales & Book Value
Annual Revenue	$42.98 million	$4.31 million	$834.89 million	$117.91 million	$256.58 million
Price / Sales	73.56	951.50	4.76	32.38	7.14
Cashflow	N/A	N/A	$0.51 per share	N/A	N/A
Price / Cash	N/A	N/A	12.39	N/A	N/A
Book Value	$6.72 per share	$3.34 per share	$3.49 per share	$10.88 per share	$6.14 per share
Price / Book	9.63	17.07	1.80	5.03	3.24
Profitability
Net Income	$-70,290,000.00	$-208,560,000.00	$294.97 million	$-411,470,000.00	$-76,970,000.00
EPS	($2.13)	($28.90)	N/A	($6.86)	($0.89)
Trailing P/E Ratio	N/A	N/A	14.58	N/A	N/A
Forward P/E Ratio	N/A	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-403.77%	N/A	N/A	-170.65%	-191.78%
Return on Equity (ROE)	-46.99%	N/A	N/A	-57.63%	-48.19%
Return on Assets (ROA)	-35.34%	N/A	N/A	-37.15%	-27.72%
Dividend
Annual Payout	N/A	N/A	$0.14	N/A	N/A
Dividend Yield	N/A	N/A	2.23%	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.01%	N/A	N/A	N/A	N/A
Current Ratio	6.53%	N/A	N/A	9.59%	6.23%
Quick Ratio	6.53%	N/A	N/A	9.43%	6.13%
Ownership Information
Institutional Ownership Percentage	75.68%	16.64%	N/A	92.93%	75.05%
Insider Ownership Percentage	10.99%	N/A	N/A	3.16%	3.39%
Miscellaneous
Employees	133	185	8,918	562	599
Shares Outstanding	48.87 million	71.95 million	633.42 million	69.81 million	92.07 million
Next Earnings Date	4/27/2021 (Estimated)	N/A	4/23/2021 (Estimated)	4/29/2021 (Confirmed)	5/6/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	FGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of FibroGen, Inc. - Yahoo Finance finance.yahoo.com - April 18 at 7:29 AM
	Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - FGEN - Yahoo Finance finance.yahoo.com - April 17 at 8:19 PM
	FGEN EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of FibroGen, Inc. feeds.benzinga.com - April 17 at 4:55 PM
	FGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Yahoo Finance finance.yahoo.com - April 17 at 2:29 PM
	FIBROGEN INVESTOR ALERT: Shareholder Class Action Lawsuit Filed - Yahoo Finance finance.yahoo.com - April 17 at 2:29 PM
	FIBROGEN INVESTOR ALERT: Shareholder Class Action Lawsuit Filed finance.yahoo.com - April 17 at 2:29 PM
	BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN - Yahoo Finance finance.yahoo.com - April 17 at 8:43 AM
	BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN - GlobeNewswire globenewswire.com - April 17 at 12:21 AM
	SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, GOEVW INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits finance.yahoo.com - April 17 at 12:20 AM
	BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FGEN benzinga.com - April 16 at 8:10 PM
	Who Has Been Buying FibroGen, Inc. (NASDAQ:FGEN) Shares? - Nasdaq nasdaq.com - April 16 at 7:20 PM
	FibroGen Deadline Alert - Yahoo Finance finance.yahoo.com - April 16 at 7:20 PM
	FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN - Yahoo Finance finance.yahoo.com - April 16 at 9:19 AM
	FIBROGEN INVESTOR ALERT: Class Action Lawsuit Filed - Yahoo Finance finance.yahoo.com - April 16 at 9:19 AM
	LAWSUITS FILED AGAINST VLDR, FGEN and DDD - Jakubowitz Law Pursues Shareholders Claims finance.yahoo.com - April 16 at 9:18 AM
	FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc. finance.yahoo.com - April 16 at 9:18 AM
	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Approaching - Yahoo Finance finance.yahoo.com - April 15 at 11:43 PM
	FGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc. - Business Wire businesswire.com - April 15 at 11:43 PM
	Portnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors - Yahoo Finance finance.yahoo.com - April 15 at 6:42 PM
	SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders - Business Wire businesswire.com - April 15 at 6:42 PM
	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Approaching finance.yahoo.com - April 15 at 6:42 PM
	Lawsuits Filed Against VLDR, LDOS and FGEN - Jakubowitz Law Pursues Shareholders Claims finance.yahoo.com - April 15 at 6:42 PM
	Portnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors benzinga.com - April 15 at 2:52 PM
	FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Yahoo Finance finance.yahoo.com - April 15 at 1:42 PM
	Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Business Wire businesswire.com - April 15 at 1:42 PM
	FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co. marketbeat.com - April 7 at 10:12 AM
	FibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of America marketbeat.com - March 31 at 7:42 AM

Date	Company	Brokerage	Action
3/31/2021	Arvinas	BMO Capital Markets	Initiated Coverage
3/30/2021	Arvinas	Cantor Fitzgerald	Boost Price Target
1/19/2021	Arvinas	Oppenheimer	Boost Price Target
12/21/2020	Arvinas	Piper Sandler	Boost Price Target
12/15/2020	Arvinas	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/15/2020	Arvinas	Smith Barney Citigroup	Boost Price Target
12/15/2020	Arvinas	Roth Capital	Boost Price Target
12/14/2020	Arvinas	HC Wainwright	Reiterated Rating
12/14/2020	Arvinas	The Goldman Sachs Group	Boost Price Target
12/14/2020	Arvinas	Wedbush	Boost Price Target
3/22/2021	I-Mab	Needham & Company LLC	Initiated Coverage
2/13/2020	I-Mab	CICC Research	Initiated Coverage
2/12/2020	I-Mab	China Renaissance Securities	Initiated Coverage
2/11/2020	I-Mab	Jefferies Financial Group	Initiated Coverage
7/29/2020	Hypera	HSBC	Upgrade
3/8/2021	Agios Pharmaceuticals	JPMorgan Chase & Co.	Reiterated Rating
3/4/2021	Agios Pharmaceuticals	SVB Leerink	Reiterated Rating
1/27/2021	Agios Pharmaceuticals	Barclays	Boost Price Target
12/28/2020	Agios Pharmaceuticals	Canaccord Genuity	Lower Price Target
12/22/2020	Agios Pharmaceuticals	Royal Bank of Canada	Lower Price Target
4/13/2021	FibroGen	Mizuho	Reiterated Rating
4/7/2021	FibroGen	Raymond James	Reiterated Rating
3/31/2021	FibroGen	Bank of America	Upgrade
5/1/2020	FibroGen	Cowen	Initiated Coverage

(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources